CAR T drives acute myeloid leukemia into submission in pre-clinical studies
A chimeric antigen receptor (CAR) T-cell construct designed to overcome difficulties with prior attempts showed good efficacy against AML in mouse models.
Treats:
Languages:
Mass General Cancer Center: Hematology Oncology
55 Fruit St.
Boston, MA 02114
Phone: 617-724-1124
Medical Education
American Board Certifications
Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.
Secure online access to your health information whenever you need it. Check appointments, communicate with your provider and pay bills online 24/7.
Mass General is recognized as a top hospital on the U.S. News Best Hospitals Honor Roll for 2023-2024.
A chimeric antigen receptor (CAR) T-cell construct designed to overcome difficulties with prior attempts showed good efficacy against AML in mouse models.
Researchers at Massachusetts General Hospital (MGH) have discovered that the interferon gamma receptor (IFNgR) signaling pathway is critical for susceptibility of glioblastoma tumors to killing by CAR T-cell immunotherapy.
Noopur Raje, MD, Marcela Maus, MD, PhD and Matthew Frigault, MD discuss the power and evolution of immune therapies, specifically, CAR T-Cell therapy in treating cancer.
Marcela Maus, MD, PhD, stands with her family beneath a custom-wrapped American Airlines A32IT plane featuring her photograph alongside superheroes Thor, Iron Man and Black Panther from the movie “Avengers: Infinity War.”
Mass General Cancer Center’s Marcela Maus, MD, PhD has been chosen to be featured in a first-of-its-kind collaboration between Stand Up To Cancer (SU2C), American Airlines, and Marvel Studios.
The 2019 Scientific Advisory Committee (SAC) meeting reflected a shift in focus from the progress of research at the MGH to the challenges facing members of the hospital’s research faculty.